Detalles de la búsqueda
1.
A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data.
BMC Cancer
; 23(1): 745, 2023 Aug 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37568126
2.
Severe hematuria in a patient receiving bevacizumab and pembrolizumab for metastatic cervical cancer: a case report.
BMC Nephrol
; 24(1): 51, 2023 03 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36899322
3.
Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System.
J Pharm Pharm Sci
; 25: 377-390, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36608646
4.
Post-marketing safety concerns of sotorasib: A disproportionality analysis based on FDA adverse event reporting system.
Heliyon
; 10(9): e30437, 2024 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38726179
5.
Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment.
Drug Saf
; 46(9): 881-895, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37418089
6.
Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system.
Front Immunol
; 14: 1169735, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37256136
7.
Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer.
Int Immunopharmacol
; 114: 109589, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36700770
8.
Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system.
CNS Neurosci Ther
; 29(9): 2705-2716, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37032639
9.
Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma.
Int Immunopharmacol
; 122: 110543, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37406395
10.
Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma.
Front Immunol
; 14: 1092385, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36756110
11.
Hematological toxicities in PARP inhibitors: A real-world study using FDA adverse event reporting system (FAERS) database.
Cancer Med
; 12(3): 3365-3375, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35871395
12.
Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China.
Front Oncol
; 12: 851522, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35515123
13.
A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
Expert Opin Drug Saf
; 21(4): 563-572, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-34918584
14.
A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System.
Clin Epidemiol
; 14: 789-802, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35789689
15.
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
Sci Rep
; 12(1): 19555, 2022 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36380085
16.
Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china.
Front Pharmacol
; 13: 818579, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36034834
17.
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib.
Sci Rep
; 12(1): 20601, 2022 11 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-36446798
18.
Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
Front Pharmacol
; 13: 862508, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35754494
19.
Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China.
Front Pharmacol
; 13: 920479, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36204237
20.
Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system.
Front Public Health
; 10: 996179, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36339230